Since the establishment of FGL1 as a high-affinity ligand of LAG-3 in 2019, the pharmaceutical industry has shown great enthusiasm in developing anti-FGL1 immunotherapy for cancer patients, especially NSCLC patients. This evidence concerns the gene FGL1 and non-small cell lung carcinoma.